Managing irritability and aggression in autism spectrum disorders in children and adolescents

Developmental Disabilities Research Reviews

Volumn 16, Issue 3, 2010, Pages 258-264

  Robb, Adelaide S ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aberrant behavior checklist; Adolescents; Aggression; Antipsy chotics; Autism spectrum disorders; Children; Irritability

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CLONIDINE; CLOZAPINE; ETIRACETAM; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MEMANTINE; OLANZAPINE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; NEUROLEPTIC AGENT;

AGGRESSION; AGITATION; ALOPECIA; AMMONIA BLOOD LEVEL; APPETITE; AUTISM; CONSTIPATION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENURESIS; FATIGUE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPERTRANSAMINASEMIA; INSOMNIA; IRRITABILITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHABDOMYOLYSIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; CHILD; CLINICAL TRIAL (TOPIC); DRUG EFFECT; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT;

ADOLESCENT; AGGRESSION; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; IRRITABLE MOOD;

EID: 79952799003     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.118     Document Type: Review

References (63)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
2. Anderson LT, Campbell M, Adams P, et al. 1989. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239.
3. Anderson LT, Campbell M, Grega DM, et al. 1984. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141: 1195-1202.
4. Belsito KM, Law PA, Kirk KS, et al. 2001. Lamo-trigine therapy of autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31: 175-181.
5. Campbell M, Anderson LT, Meier M, et al. 1978. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17: 640-655.
6. Chen NC, Bedair HS, McKay B. 2001. Clozapine in the treatment of aggression in an adolescent with autistic disorder (letter). J Clin Psychiatry 62:479-480.
7. Cohen IL, Campbell M, Posner D, et al. 1980. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Psychiatry 19:665-677.
8. Corson AH, Barkenbus JE, Posey DJ, et al. 2004. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531-1536.
9. Epperson CN, McDougle CJ, Anand A, et al. 1994. Lithium augmentation of fluvoxamine in autistic disorder: a case report. J Child Adolesc Psychpharmacol 4:201-207.
10. Erickson CA, Posey DJ, Stigler KA, et al. 2007. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 191:141-147.
11. Exhorn KS. 2005. The autism sourcebook: everything you need to know about diagnosis, treatment, coping and healing. New York, NY: Harper Collins.
12. Fankhauser MP, Karumanchi VC, German ML, et al. 1992. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53: 77-82.
13. Fava M. 1997. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 20:427-451.
14. Findling RL, McNamara NK, Gracious BL, et al. 2004. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287-294.
15. Fombonne E, Zakarian R, Bennett A, et al. 2006. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 118: e139-e150.
16. Fukuda T, Sugie H, Ito M, et al. 2001. Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No To Hattatsu 33:314-318.
17. Gabriels RL, Cuccaro ML, Hill DE, et al. 2005. Repetitive behaviors in autism: relationships with associated clinical features. Res Dev Disabil 26:169-181.
18. Gualtieri CT, Golden RN, Fahs JJ. 1983. New developments in pediatric psychopharmacology. J Dev Behav Pediatr 4:202-209.
19. Handen BL, Sahl R, Hardan AY. 2008. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 29: 303-308.
20. Hassler F and Reis O. 2010. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Dev Disabil Res Rev 16:265-272.
21. Hardan AY, Jou RJ, Handen BL. 2005. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35:387-391.
22. Hellings JA, Weckbaugh M, Nickel EJ, et al. 2005. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychpharmacol 15:682-692.
23. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. 2001. An open trial of Divalproex sodium in autism spectrum disorders. J Clin Psychiatry 62:530-534.
24. Hollander E, Wasserman S, Swanson EN, et al. 2006. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16: 541-548.
25. Jaselskis CA, Cook EH, Fletcher KE, et al. 1992. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327.
26. Johnson CP, Myers SM; American Academy of Pediatrics Council on Children With Disabilities. 2007. Identification and evaluation of children with autism spectrum disorders. Pediatrics 120:1183-1215.
27. Karakaya P, Yis U, Kurul SH, et al. 2010. Rhabdomyolysis associated with olanzapine treatment in a child with autism. Ped Emer Care 26:41-42.
28. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. 2002. Open-label study of Olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22: 455-460.
29. King BH. 2000. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disorders 30:439-445.
30. King BH, Wright DM, Handen BL, et al. 2001. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40:658-665.
31. Lecavalier L. 2006. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics and empirical classification. J Autism Dev Disord 36: 1101-1114.
32. Luby J, Mrakotsky C, Stalets MM, et al. 2006. Risperidone in preschool children with autistic disorder: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575-587.
33. Luiselli JK, Blew P, Keane J, et al. 2000. Pharmacotherapy for severe aggression in a child with autism: "open-label" evaluation of multiple medications on response frequency and intensity of behavioral intervention. J Behav Ther Exp Psychiatry 31:219-230.
34. Malone RP, Cater J, Sheikh RM, et al. 2001. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 22: 455-460.
35. Malone RP, Delaney MA, Hyman SB, et al. 2007. Ziprasidone in adolescents with autism: an open-label pilot study. J Am Acad Child Adolesc Psychiatry 17:779-790.
36. Marcus R, Owen R, Kamen L, et al. 2009. A double-blind, randomized, placebo-controlled study of fixed-dose aripiprazole in children and adolescents with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119.
37. Martin A, Koenig K, Scahill L, et al. 1999. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9: 99-107.
38. Mazzone L, Ruta L. 2006. Topiramate in children with autistic spectrum disorders. Brain Dev 28:668.
39. McCracken JT, McGough J, Shah B, et al. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321.
40. McDougle CJ, Kem DL, Posey DJ. 2002. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921-927.
41. McDougle CJ, Scahill L, Aman MG, et al. 2005. Risperidone for the core symtpom domains of autism: results from the study by the autism network of the research units on pediat-ric psychopharmacology. Am J Psychiatry 162:1142-1148.
42. Miral S, Gencer O, Inal-Emiroglu FN, et al. 2008. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17:1-8.
43. Mula M, Monaco F. 2009. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 11:1-9.
44. Nagaraj R, Singhi P, Malhi P. 2006. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450-455.
45. Nevels RM, Dehon EE, Alexander K, et al. 2010. Psychopharmacology of aggression in children and adolescents with primary neuro-psychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharm 18:184-201.
46. Olsson I, Steffenburg S, Gillberg C. 1988. Epilepsy in autism and autistic-like conditions. Arch Neurol 45:666-668.
47. Owen R, Sikich L, Marcus R, et al. 2009. A multicenter, double-blind, randomized, placebo-controlled, flexible-dose, parallel-group study of aripiprazole in the treatment of irritability in children and adolescents (6-17 years) with autistic disorder. Pediatrics 124:1533-1540.
48. Perry R, Campbell M, Adams P, et al. 1989. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Psychiatry 28:87-92.
49. Posey DJ, Putney JI, Sasher TM, et al. 2004. Guanfacine treatment of hyperactivity and inattention in autism: a retrospective analysis of 80 cases. J Child Adol Psychopharmacol 14:233-241.
50. Potenza MN, Holmes JP, Kanes SJ, et al. 1999. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37-44.
51. Research Unit on Pediatric Psychopharmacology (RUPP) Autism Network. 2002. Risperidone in children with autism and serious behavioural problems. New Engl J Med 347: 314-321.
52. Research Unit on Pediatric Psychopharmacology (RUPP) Autism Network. 2005. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162: 1361-1369.
53. Robb AS, Lee RH, Cooper EB, et al. 2008. Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents. J Child Adol Psychopharmacol 18:99-107.
54. Rugino TA, Samsock TC. 2002. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 23:225-230.
55. Shea S, Turgay A, Carrol A, et al. 2004. Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-e641.
56. Stigler KA, Diener JT, Kohn AE, et al. 2009. Ari-piprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week prospective, open-label study. J Child Adol Psychopharmacol 19: 265-274.
57. Stigler KA, Posey DJ, McDougle CJ. 2004. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder. J Child Adol Psychopharmacol 14:445-463.
58. Troost PW, Lahuis BE, Steenhuis MP, et al. 2005. Long term effects of risperidone in children with autism spectrum disordersL a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137-1144.
59. Uvebrandt P, Bauziene R. 1994. Intractible epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25:284-289.
60. Valicenti-McDermott MR, Demb H. 2006. Clii-cal effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolsc Psychopharmacol 16:549-560.
61. Wasserman S, Iyengar R, Chaplin WF, et al. 2006. Levetiracetam versus placebo in childhood and adolescen autism: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 21:363-367.
62. Yokoyama H, Hirose M, Haginoya K, et al. 2002. Clinical evaluation of treatment with fluvox-amine, a selective serotonin reuptake inhibitor in children with autistic disorder. No To Hattatsu 34:249-253.
63. Zuddas A, Ledda MG, Fratta A. 1996. Clinical effects of clozapine on autistic disorder (letter). Am J Psychol 153:738.